Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20165421 | 1.00 | L3MBTL1 (0.55) | L3MBTL1TDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL2342765 | 0.86 | PTGDR2 (0.68) | L3MBTL1TDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL2317111 | 0.83 | KMT2A (0.53) | L3MBTL1TDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL2601637 | 0.83 | KMT2A (0.53) | L3MBTL1TDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1382747 | 0.83 | PTGDR2 (0.73) | L3MBTL1TDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL3312018 | 0.80 | MEN1 (0.51) | L3MBTL1MEN1KMT2AALDH1A1PTGDR2 | |
| SCHEMBL9787048 | 0.80 | L3MBTL1 (0.73) | L3MBTL1TDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL16382639 | 0.77 | MEN1 (0.48) | L3MBTL1MEN1KMT2AALDH1A1PTGDR2 | |
| SCHEMBL9787058 | 0.76 | L3MBTL1 (0.71) | L3MBTL1TDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL2398594 | 0.76 | MAPT (0.67) | L3MBTL1TDP1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109982993-B | Asymmetrically substituted dienyl diphenyl ethers, their preparation and use | 赢创运营有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3541773-B1 | ASYMMETRICALLY SUBSTITUTED BIS-ALKENYL DIPHENYL ETHERS, THEIR PREPARATION AND USE | EVONIK OPERATIONS GMBH (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-20190367652-A1 | ASYMMETRICALLY SUBSTITUTED BIS-ALKENYL DIPHENYL ETHERS, THEIR PREPARATION AND USE | EVONIK TECHNOCHEMIE GMBH (DE) | 2019-12-05 | — | — | US | disclosed |
| EP-3541773-A1 | ASYMMETRICALLY SUBSTITUTED BIS-ALKENYL DIPHENYL ETHERS, THEIR PREPARATION AND USE | Evonik Technochemie GmbH (DE) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091253-A1 | ASYMMETRICALLY SUBSTITUTED BIS-ALKENYL DIPHENYL ETHERS, THEIR PREPARATION AND USE | EVONIK TECHNOCHEMIE GMBH (DE) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190367652-A1 | ASYMMETRICALLY SUBSTITUTED BIS-ALKENYL DIPHENYL ETHERS, THEIR PREPARATION AND USE | ITGB3, C9, CBR3 | L3MBTL1 1744/4885TDP1 3692/4885MEN1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.